# Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects

> **NCT02266485** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBB 515 BS
- **DRUG:** Pravastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02266485
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** 1998-09
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02266485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02266485, "Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02266485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*